Merck is granted rights to Xencor's monoclonal antibody patent

07/3/2013 | Genetic Engineering & Biotechnology News

Merck & Co. secured nonexclusive licensing rights to one of Xencor's engineering patents for a monoclonal antibody. The deal allows Merck to use the patent for an undisclosed product and gives it an option to license the same patent for future products. Xencor is entitled to an upfront payment, yearly maintenance fees and potential milestone payments and sales royalties.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD